HHS Eases Enforcement on Six Compounded Peptides: What the New Policy Does and Doesn't Mean
On October 28, 2026, the US Department of Health and Human Services filed a draft policy that changes how regulators will treat pharmacy compounding of six peptides. The notice was published in the Federal Register on October 30. The headlines made it sound bigger than it is, so here is a plain reading of what it does and what it leaves alone.
What the policy says
HHS says it does not intend to take enforcement action against a state-licensed pharmacy, a federal facility, or a licensed physician that compounds a drug using one of six peptides: BPC-157, epitalon, KPV, MOTS-c, Semax, or TB-500. That protection applies only when ten conditions are met. According to AJMC, HHS describes the requirements as patient-specific prescriptions, traceable ingredients, quality testing, and safety reporting.
The policy is explicitly interim. It applies only until FDA finishes rulemaking that decides, peptide by peptide, whether each one goes on the list of bulk substances pharmacies may compound.
What it does not do
- It does not approve any peptide. HHS said the policy neither grants FDA approval nor establishes that these compounds are safe or effective.
- It does not add anything to the 503A bulks list. That decision still belongs to FDA's rulemaking.
- It does not make "research use only" vials a legal route for personal use. One stated goal is to steer people away from foreign research-use-only products toward a more controlled, prescription-based option, according to a legal summary. FDA has also sent warning letters this year to websites selling products such as retatrutide and tirzepatide alongside bacteriostatic water, including this one.
Why it is contested
AJMC reports that the policy came from the Secretary's office rather than from FDA, and that FDA's own career scientists had recommended against adding the peptides reviewed at a July advisory committee meeting, even though the committee itself backed six of them. The Partnership for Safe Medicines has petitioned FDA to disregard that vote and block compounding of these peptides.
Written comments were due two weeks after the October 30 publication, and HHS has said it may revisit the policy if a safety signal or product-quality problem appears. State regulators are not bound by it, and some may not follow it.
What it means for you
- If a prescriber has you on a compounded peptide, it should come from a licensed pharmacy against a prescription written for you.
- Ask the pharmacy where the active ingredient comes from, and keep a record of each vial's lot number. That turns any future recall into a quick check.
- The policy covers only these six peptides. It says nothing about the many other compounds sold online.
- Expect the rules to keep moving while rulemaking is pending.
DoseCurve's calculator only does the arithmetic for a vial you already have. It cannot tell you whether that vial is legitimate, so that check belongs to you and your pharmacist.
This article summarizes public reporting and legal commentary for general information and is not medical or legal advice. Content was rephrased for compliance. Talk to your healthcare provider before using any compounded peptide.
This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication or treatment protocol.